Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

357.67
-1.9100-0.53%
Volume:161.78K
Turnover:57.85M
Market Cap:40.77B
PE:63.99
High:360.19
Open:351.73
Low:351.41
Close:359.58
52wk High:385.22
52wk Low:253.95
Shares:114.00M
Float Shares:85.69M
Volume Ratio:0.93
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.59
EPS(LYR):2.47
ROE:14.66%
ROA:7.46%
PB:7.88
PE(LYR):144.81

Loading ...

Amgen and BeiGene Advance Subcutaneous Formulation of FIC Bispecific Antibody into Phase III Trial

Deep News
·
Jul 23

3 U.S. Drug Manufacturing Stocks Investors Are Watching As Tariffs Rise

Simply Wall St.
·
Jul 22

Press Release: Beone Medicines to Announce Second Quarter 2026 Financial Results on August 5

Dow Jones
·
Jul 17

BeOne Medicines (ONC) Stock Looks Expensive Even With Strong Pipeline Hopes

Simply Wall St.
·
Jul 16

How Chemotherapy-Free Phase 3 MCL Success At BeOne Medicines (ONC) Has Changed Its Investment Story

Simply Wall St.
·
Jul 15

BeOne Medicines (ONC) Gets a Buy from Barclays

TIPRANKS
·
Jul 14

BeOne Medicines Advances Sonrotoclax Formulation Study, Signaling Progress in ONC Pipeline

TIPRANKS
·
Jul 10

BeOne Medicines treatment of pancreatic cancer granted orphan status

TIPRANKS
·
Jul 09

BEIGENE Awards Aggregate 33,400 Restricted Stock Units Represented by American Depositary Shares

Stock News
·
Jul 08

BEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib

Stock News
·
Jul 03

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) and Zevra Therapeutics (ZVRA)

TIPRANKS
·
Jul 01

BEIGENE Reports Positive Phase 3 Trial Results for BRUKINSA® in First-Line Treatment of Mantle Cell Lymphoma

Stock News
·
Jun 30

BeOne Medicines' Potential Chemotherapy-Free Lymphoma Treatment Meets Primary Endpoint in Phase 3 Study

MT Newswires Live
·
Jun 30

Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI

Dow Jones
·
Jun 29

BEIGENE Subsidiary to Pay Approximately 446 Million Yuan in Back Taxes, No Penalty Involved

Stock News
·
Jun 26

BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope

TIPRANKS
·
Jun 26

BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial

TIPRANKS
·
Jun 19

BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors

TIPRANKS
·
Jun 19

BEIGENE Announces Grant of Share Options, Restricted Share Units, and Performance Share Units

Stock News
·
Jun 18

BeOne Revenue Expected to Grow on Strong Brukinsa Sales -- Market Talk

Dow Jones
·
Jun 18